Who makes "Prophylactic" delayed ADLI?

"Prophylactic" delayed ADLI is developed by Abramson Cancer Center at Penn Medicine.

What development phase is "Prophylactic" delayed ADLI in?

"Prophylactic" delayed ADLI is in Phase 1.

Last reviewed 2026-04-20 · How we verify

"Prophylactic" delayed ADLI

Abramson Cancer Center at Penn Medicine · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	"Prophylactic" delayed ADLI
Sponsor	Abramson Cancer Center at Penn Medicine
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

"Prophylactic" delayed ADLI CI brief — competitive landscape report
"Prophylactic" delayed ADLI updates RSS · CI watch RSS
Abramson Cancer Center at Penn Medicine portfolio CI